John S. Sundy

Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment

John S. Sundy, Herbert S. B. Baraf, Robert A. Yood et al. · JAMA · 2011 · 516 citations · Full text

Pharmacy, Pharmacotherapy, Biopharmaceutics +14

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase

Nancy J. Ganson, Susan J. Kelly, Edna Scarlett et al. · Arthritis Research & Therapy · 2005 · 343 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy

Mark C. Genovese, Kenneth Kalunian, Jacques‐Eric Gottenberg et al. · JAMA · 2019 · 327 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

Robert Terkeltaub, John S. Sundy, H. Ralph Schumacher et al. · Annals of the Rheumatic Diseases · 2009 · 302 citations · Full text

Medicine, Immunology, Pharmacotherapy +17

Leukemia Inhibitory Factor, Oncostatin M, IL-6, and Stem Cell Factor mRNA Expression in Human Thymus Increases with Age and Is Associated with Thymic Atrophy

Laura P. Hale, John S. Sundy, Janice M. Massey et al. · The Journal of Immunology · 2000 · 299 citations

Life Sciences, Cell Biology, Immunology +17